<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genet</journal-id><journal-title>BMC Genetics</journal-title><issn pub-type="epub">1471-2156</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2156-10-55</article-id><article-id pub-id-type="pmid">19754929</article-id><article-id pub-id-type="doi">10.1186/1471-2156-10-55</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of two common polymorphisms in the 3' untranslated regions of estrogen receptor &#x003b2; on mRNA stability and translatability</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Putnik</surname><given-names>Milica</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>milica.putnik@ki.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Zhao</surname><given-names>Chunyan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>chunyan.zhao@ki.se</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Gustafsson</surname><given-names>Jan-&#x000c5;ke</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jan-ake.gustafsson@ki.se</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Dahlman-Wright</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>karin.dahlman-wright@ki.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biosciences and Nutrition, Novum, Karolinska Institutet, S-141 57 Huddinge, Sweden</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>9</month><year>2009</year></pub-date><volume>10</volume><fpage>55</fpage><lpage>55</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2156/10/55"/><history><date date-type="received"><day>14</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Putnik et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Putnik et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Putnik Milica milica.putnik@ki.se </dc:author><dc:title> Effects of two common polymorphisms in the 3' untranslated regions of estrogen receptor &#x003b2; on mRNA stability and translatability </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Genetics 10(1): 55-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2156(2009)10:1&#x0003c;55&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2156</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The present study represents the first attempt to functionally characterize two common single nucleotide polymorphisms (SNPs) in the 3'untranslated regions (3'UTRs) of estrogen receptor &#x003b2; (ER&#x003b2;), focusing on the differences between alleles with regard to mRNA stability and translatability. These two ER&#x003b2; SNPs have been investigated for association with disease in a large number of reports.</p></sec><sec><title>Results</title><p>Here we examined allelic expression in breast tumor samples from heterozygous individuals. A significant difference in mRNA levels of the two alleles was observed for one of the SNPs. A cell model system was employed to further investigate potential molecular effects of the two SNPs. We used a modified plasmid, containing the ER&#x003b2; promoter and ER&#x003b2; 3'UTRs which include the different alleles of investigated SNPs. Quantitative Real-Time PCR was used to determine mRNA levels after inhibition of transcription by actinomycin D, and a luciferase assay was used to determine protein levels. The obtained results suggested that there was no difference in mRNA stability or translatability between the alleles of investigated SNPs.</p></sec><sec><title>Conclusion</title><p>Our results indicate that observed associations between ER&#x003b2; 3'UTR SNPs and disease susceptibility are due to linkage disequilibrium with another gene variant, rather than the variant itself being the susceptibility factor.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The steroid hormone estradiol-17&#x003b2; exerts its functions through binding to estrogen receptors (ERs), ER&#x003b1; and ER&#x003b2;. The ERs belong to the nuclear receptor superfamily, a family of ligand-regulated transcription factors [<xref ref-type="bibr" rid="B1">1</xref>]. Both receptors, when ligand-activated, modulate gene expression and subsequently trigger a broad repertoire of physiological responses.</p><p>Estrogen signaling is involved in the regulation of development, growth and function of diverse systems, including human reproductive organs, mammary glands and skeletal and nervous systems. Aberrations in estrogen signaling have been proposed to be associated with several diseases, such as breast, endometrial, and ovarian cancers, osteoporosis, eating disorders and depression [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Five ER&#x003b2; isoforms, designated ER&#x003b2;1-5, have been reported in humans [<xref ref-type="bibr" rid="B5">5</xref>]. Among them, the presence of a corresponding protein has been clearly demonstrated only for ER&#x003b2;1 (wild type) and ER&#x003b2;2. The ER&#x003b2;1-5 transcripts have unique sequences in place of exon 8, and thus different 3'untranslated region (3'UTRs). Single nucleotide polymorphisms (SNPs) in 3'UTRs have been identified only for ER&#x003b2;1 and ER&#x003b2;2. It has been shown that both ER&#x003b2;1 and ER&#x003b2;2 transcripts are regulated by the same promoter, designated as promoter 0N [<xref ref-type="bibr" rid="B6">6</xref>]. Promoter 0N was first described by Li et al. [<xref ref-type="bibr" rid="B7">7</xref>], and shown to contain both TATA box and initiator element (Inr) and putative binding sites for transcription factors AP-1, AML-1a and Oct-1.</p><p>Two SNPs in the ER&#x003b2; gene have been studied for association with a number of diseases. They are referred to as rs4986938 and rs928554 [<xref ref-type="bibr" rid="B8">8</xref>]. rs4986938 is a G&#x02194;A transition in exon 8, corresponding to ER&#x003b2;1 3'UTR. rs928554 is a G&#x02194;A transition in exon 9, corresponding to ER&#x003b2;2 3'UTR (Figure <xref ref-type="fig" rid="F1">1A</xref>). The distribution of these SNPs in some human populations is shown in Table <xref ref-type="table" rid="T1">1</xref> and Table <xref ref-type="table" rid="T2">2</xref>.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Locations of the two SNPs in ER&#x003b2; 3'UTRs and reporter constructs used in transient transfection assays</bold>. <bold>A</bold>. rs4986938 is positioned in the 3'UTR of exon 8 and rs928554 in the 3'UTR exon 9. Exons are represented as shaded boxes, 3'UTRs as white boxes, and introns as connecting lines. Exon 9 is an alternatively spliced last exon (represented as a dashed line), which gives rise to the ER&#x003b2; variant ER&#x003b2;2. <bold>B</bold>. Luciferase reporter constructs used in transient transfection assays were generated from a promoterless PGL3 basic plasmid. The ER&#x003b2; promoter was introduced using restriction enzymes <italic>MluI </italic>and <italic>XhoI</italic>. <italic>XbaI </italic>and <italic>BamHI </italic>were used to replace the SV40 poly(A) signal with ER&#x003b2; 3'UTR sequences.</p></caption><graphic xlink:href="1471-2156-10-55-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Frequency of rs4986938 in selected studies</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Studied populations</bold></td><td align="center"><bold>Sample size</bold></td><td align="center" colspan="2"><bold>Allele frequency (%)*</bold></td><td align="center"><bold>Study</bold></td></tr><tr><td></td><td></td><td align="center"><bold>G</bold></td><td align="center"><bold>A</bold></td><td></td></tr></thead><tbody><tr><td align="left"><bold>Caucasians</bold></td><td align="center">567</td><td align="center">62.0</td><td align="center">38.0</td><td align="center">Westberg et al. [<xref ref-type="bibr" rid="B15">15</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Caucasians</bold></td><td align="center">1376</td><td align="center">65.8</td><td align="center">34.2</td><td align="center">Kisiel et al. [<xref ref-type="bibr" rid="B16">16</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Caucasians</bold></td><td align="center">457</td><td align="center">68.3</td><td align="center">31.7</td><td align="center">Forsti et al. [<xref ref-type="bibr" rid="B18">18</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Caucasians</bold></td><td align="center">628</td><td align="center">65.0</td><td align="center">35.0</td><td align="center">Maguire et al. [<xref ref-type="bibr" rid="B19">19</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Caucasians</bold></td><td align="center">1107</td><td align="center">62.0</td><td align="center">38.0</td><td align="center">Nilsson et al. [<xref ref-type="bibr" rid="B39">39</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Caucasians</bold></td><td align="center">1702</td><td align="center">63.0</td><td align="center">37.0</td><td align="center">Ichikawa et al. [<xref ref-type="bibr" rid="B40">40</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Caucasians</bold></td><td align="center">862</td><td align="center">62.0</td><td align="center">38.0</td><td align="center">Rexrode et al. [<xref ref-type="bibr" rid="B43">43</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Asians</bold></td><td align="center">526</td><td align="center">86.5</td><td align="center">13.5</td><td align="center">Lee et al. [<xref ref-type="bibr" rid="B41">41</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Asians</bold></td><td align="center">776</td><td align="center">86.0</td><td align="center">14.0</td><td align="center">Iwasaki et al. [<xref ref-type="bibr" rid="B44">44</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>South Americans</bold></td><td align="center">758</td><td align="center">67.0</td><td align="center">33.0</td><td align="center">Iwasaki et al. [<xref ref-type="bibr" rid="B44">44</xref>]</td></tr></tbody></table><table-wrap-foot><p>* Includes cases and controls</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Frequency of rs928554 in selected studies</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Studied populations</bold></td><td align="center"><bold>Sample size</bold></td><td align="center" colspan="2"><bold>Allele frequency (%)*</bold></td><td align="center"><bold>Study</bold></td></tr><tr><td></td><td></td><td align="center"><bold>G</bold></td><td align="center"><bold>A</bold></td><td></td></tr></thead><tbody><tr><td align="left"><bold>Caucasians</bold></td><td align="center">723</td><td align="center">43.0</td><td align="center">57.0</td><td align="center">Maguire et al. [<xref ref-type="bibr" rid="B19">19</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Caucasians</bold></td><td align="center">1107</td><td align="center">44.0</td><td align="center">56.0</td><td align="center">Nilsson et al. [<xref ref-type="bibr" rid="B39">39</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Asians</bold></td><td align="center">244</td><td align="center">38.6</td><td align="center">61.4</td><td align="center">Maruyama et al. [<xref ref-type="bibr" rid="B17">17</xref>]</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Asians</bold></td><td align="center">747</td><td align="center">38.0</td><td align="center">62.0</td><td align="center">JSPN [<xref ref-type="bibr" rid="B45">45</xref>]</td></tr></tbody></table><table-wrap-foot><p>* Includes cases and controls</p></table-wrap-foot></table-wrap><p>rs4986938 was first reported in a study on anorexia nervosa by Rosencrantz et al. [<xref ref-type="bibr" rid="B9">9</xref>]. rs928554 was first described by Nilsson et al., and both this SNP and rs4986938 were found to be associated with bulimia [<xref ref-type="bibr" rid="B10">10</xref>]. In another study, both SNPs have been associated with increased homocysteine levels [<xref ref-type="bibr" rid="B11">11</xref>]. Furthermore, rs4986938 has been associated with osteoporosis in women [<xref ref-type="bibr" rid="B12">12</xref>], ovulatory dysfunctions [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>], Parkinson's [<xref ref-type="bibr" rid="B15">15</xref>] and Grave's disease [<xref ref-type="bibr" rid="B16">16</xref>]. In one study, rs928554 was associated with preeclampsia [<xref ref-type="bibr" rid="B17">17</xref>]. The allele frequencies of these SNPs in some case control studies are presented in Table <xref ref-type="table" rid="T3">3</xref>. This table shows that different alleles are associated with the highest disease incidence for different diseases.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Allele frequencies of rs4986938 and rs928554 in cases versus controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>SNP</bold></td><td align="center"><bold>Allele</bold></td><td align="center"><bold>Disease</bold></td><td align="center"><bold>Cases (%)</bold></td><td align="center"><bold>Controls (%)</bold></td><td align="center"><bold>Study</bold></td></tr></thead><tbody><tr><td align="left"><bold>rs4986938</bold></td><td align="center">A</td><td align="center">ovulatory dysfunctions</td><td align="center">25.8</td><td align="center">10.3</td><td align="center">Sundarrajan C et al. [<xref ref-type="bibr" rid="B13">13</xref>]</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>rs4986938</bold></td><td align="center">G</td><td align="center">Parkinson's disease</td><td align="center">75.0</td><td align="center">60.7</td><td align="center">Westberg et al. [<xref ref-type="bibr" rid="B15">15</xref>]</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>rs4986938</bold></td><td align="center">A</td><td align="center">Grave's disease</td><td align="center">38.0</td><td align="center">32.7</td><td align="center">Kisiel et al. [<xref ref-type="bibr" rid="B16">16</xref>]</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>rs4986938</bold></td><td align="center">A</td><td align="center">vascular dementia</td><td align="center">51.0</td><td align="center">38.0</td><td align="center">Dresner-Pollak et al. [<xref ref-type="bibr" rid="B46">46</xref>]</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>rs4986938</bold></td><td align="center">G</td><td align="center">bulimia</td><td align="center">43.0</td><td align="center">26.0</td><td align="center">Nilsson et al. [<xref ref-type="bibr" rid="B10">10</xref>]</td></tr><tr><td align="left"><bold>rs928554</bold></td><td align="center">G</td><td></td><td align="center">61.0</td><td align="center">43.0</td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>rs928554</bold></td><td align="center">A</td><td align="center">preeclampsia</td><td align="center">71.3</td><td align="center">60.8</td><td align="center">Maruyama et al. [<xref ref-type="bibr" rid="B17">17</xref>]</td></tr></tbody></table></table-wrap><p>Studies of associations between these polymorphisms and breast cancer risk indicate that they do not have an effect <italic>per se </italic>[<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. However, association is found for haplotypes which contain either both SNPs [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B21">21</xref>] or rs4986938 solely [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>3'UTRs are regulatory elements which can control protein expression, primarily through effects on mRNA stability but also through transcript translatability [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. 3'UTRs control poly(A) tail length either through polyadenylation (due to the presence of polyadenylation AU signals) or deadenylation (e.g. binding of the PUF proteins) [<xref ref-type="bibr" rid="B25">25</xref>]. It has been reported that poly(A) tails correlate with translation, by poly(A) binding proteins interacting with translation factors at the 5' cap site. In most cases, long poly(A) tails are associated with induction and short poly(A) tails with repression of translation [<xref ref-type="bibr" rid="B24">24</xref>]. Loss of the poly(A) tail is thought to promote mRNA degradation by facilitating attack by both the exosome complex [<xref ref-type="bibr" rid="B26">26</xref>] and the decapping complex [<xref ref-type="bibr" rid="B27">27</xref>]. However to our knowledge, no studies have been published regarding mechanisms how SNPs regulate mRNA stability and/or translatability.</p><p>Recent studies show that 3'UTRs contain targets for micro RNAs (miRNAs) [<xref ref-type="bibr" rid="B28">28</xref>]. miRNAs are short endogenous RNAs (~ 23 nt) that play important gene-regulatory roles by pairing to the mRNAs of protein-coding genes to direct their posttranscriptional repression, suggesting an additional mechanism for 3'UTR-controlled protein expression.</p><p>In this study, we first examined whether ER&#x003b2; mRNAs, corresponding to the different investigated alleles, were expressed at equal levels in breast tumor samples from heterozygous individuals. Both ER&#x003b2; variants are expressed at significant amounts in breast tissue [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>], which makes it a good system to study endogenous expression of ER&#x003b2; mRNA. It is also generally acknowledged that ER&#x003b2; has an important role in the development of this disease [<xref ref-type="bibr" rid="B31">31</xref>]. Next, we used an <italic>in vitro </italic>system to investigate if different alleles of the two commonly assayed SNPs in the ER&#x003b2; 3'UTRs display differences in transcript stability or translatability, thus providing a molecular explanation for the observed disease associations.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Allelic expression assay</title><p>Primary breast tumor tissue samples from patients with invasive ductal carcinoma and undergoing breast cancer surgery were frozen in liquid nitrogen immediately after resection and stored at -80&#x000b0;C until use.</p><p>Genomic DNA from these samples was extracted using GenElute&#x02122; Mammalian Genomic DNA Miniprep Kit (SIGMA). RNA was extracted using Invitrogen's TRIzol LS Reagent protocol for mammalian tissues. 1 &#x003bc;g of total RNA was treated with Invitrogen's DNase I (Amplification Grade) to eliminate the remains of DNA, and then converted into cDNA using Invitrogen's protocol for SuperScript<sup>&#x000ae; </sup>III Reverse Transcriptase.</p><p>To amplify the 3'UTRs that contain the studied SNPs, in both genomic DNA and cDNA, PCR was performed. The basic PCR protocol for Invitrogen's Taq DNA Polymerase was used, with specific primers: ER&#x003b2;1-F (5'-TGCTGCTGGAGATGCTGAAT-3') and ER&#x003b2;1-R (5'-TCACACCGACTCCTGAGAGTTG-3') for ER&#x003b2;1 3'UTR, and ER&#x003b2;2-F (5'-GGGCAGAAAAGGCCTCTCA-3') and ER&#x003b2;2-R (5'-GAAGCCTCAGCTTTCTACATTGG-3') for ER&#x003b2;2 3'UTR. The amplified fragments were sequenced on Applied Biosystems' 3730 &#x000d7; l DNA Analyzer in Macrogen DNA Sequencing Service [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>Peak heights from sequencing reactions of genomic DNA and cDNA were measured for each allele for the two SNPs. Twenty samples were analyzed, and for each SNP under investigation five showed to be heterozygotes, i.e. informative for the assay. For each sample and SNP, the relative height of the peak for the cDNA versus the genomic DNA was determined for a particular allele.</p></sec><sec><title>ER&#x003b2;-Promoter-Luciferase-3'UTR-reporter constructs</title><p>Plasmid constructs were generated by cloning the ER&#x003b2; promoter and different ER&#x003b2; 3'UTR sequences into a promoterless PGL3 basic plasmid (Promega, Madison, W1).</p><p>A 1081 bp fragment of ER&#x003b2; promoter 0N was amplified from human genomic DNA (Roche), using Expand Long Template PCR System (Roche, 150 U; recommended for fragments longer than 1 kb) and specific forward (5'-TATT<bold>ACGCGT</bold>TCCTGCTGGGGTGGGTGAG-3') and reverse primers (5'-TTAT<bold>CTCGAG</bold>CGAAGGGGCGCTTACCTT-3'). The primers were designed to incorporate restriction sites for enzymes MluI and XhoI (marked bold in the primer sequences), respectively. The promoterless PGL3 basic plasmid and the amplified fragment were digested with MluI and XhoI. The amplified fragment was inserted into the MluI/XhoI restriction sites of PGL3 basic, creating plasmid ER&#x003b2;promPGL3 (Figure <xref ref-type="fig" rid="F1">1B</xref>).</p><p>A 933 bp fragment of ER&#x003b2; exon 8, corresponding to ER&#x003b2;1 3'UTR, was amplified from human genomic DNA (Roche), using Invitrogen's Platinum<sup>&#x000ae; </sup>Taq DNA Polymerase protocol (5 U/&#x003bc;l), and forward (5'-TATT<bold>TCTAGA</bold>GCAGCCCGGCAGAGGACAG-3') and reverse primers (5'-TTAT<bold>GGATCC</bold>CCACATTGCCCCAGGGAAACACT-3'), containing restriction sites for enzymes XbaI and BamHI (marked bold in the primer sequences), respectively. The ER&#x003b2;promPGL3 plasmid and the ER&#x003b2;1 3'UTR fragment were digested with XbaI and BamHI. The ER&#x003b2;1 3'UTR fragment was inserted into the XbaI/BamHI restriction sites of the ER&#x003b2;promPGL3 plasmid, replacing the SV40 poly(A) signal, and creating plasmid ER&#x003b2;promPGL3ER&#x003b2;1UTR.</p><p>A 1380 bp fragment of ER&#x003b2; exon 9, corresponding to ER&#x003b2;2 3'UTR was amplified from human genomic DNA (Roche), using Roche's Expand Long Template PCR System (same protocol as above), and forward (5'-TATT<bold>TCTAGA</bold>GAAAAGGCCTCTCAAACACTC-3') and reverse primers (5'-TTAT<bold>GGATCC</bold>TAAATGCCAAACTACCGACTT-3'), containing restriction sites for enzymes XbaI and BamHI (marked bold in the primer sequences), respectively. The amplified fragment was inserted into the ER&#x003b2;promPGL3 plasmid (same as above), creating plasmid ER&#x003b2;promPGL3ER&#x003b2;2UTR (Figure <xref ref-type="fig" rid="F1">1B</xref>).</p><p>Both amplified and cloned fragments contain the G nucleotide at the respective SNP positions. Mutagenesis was performed in order to generate the corresponding A alleles, using the QuikChange<sup>&#x000ae; </sup>Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California) and two primer sets: ER&#x003b2;1MutF (5'-GCCCACAGAGGTCACAAGCTGAAGCGTGAACTC-3') and ER&#x003b2;1MutR (5'-GAGTTCACGCTTCAGCTTGTGACCTCTGTGGGC-3') for ER&#x003b2;1 3'UTR, and ER&#x003b2;2MutF (5'-CAATGATCCCAGAGGGAAATTGAAGTGAAAATGTTACCC-3') and ER&#x003b2;2MutR (5'-GGGTAACATTTTCACTTCAATTTCCCTCTGGGATCATTG-3') for ER&#x003b2;2 3'UTR. The final products were four different constructs, two for the each studied SNP: ER&#x003b2;promPGL3ER&#x003b2;1UTR-G and ER&#x003b2;promPGL3ER&#x003b2;1UTR-A for rs4986938, and ER&#x003b2;promPGL3ER&#x003b2;2UTR-G and ER&#x003b2;promPGL3ER&#x003b2;2UTR-A for rs928554. The sequences of each pair of constructs differed only in the SNP under investigation. The sequences of all constructs were verified by DNA sequencing.</p></sec><sec><title>Transient transfection assays</title><p>Luciferase activity was measured in three human cell lines - human fetal kidney HEK293 cells, cervical cancer HeLa cells and breast adenocarcinoma MCF7 cells. HEK293 and HeLa represent ER-negative cell lines [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>], whereas MCF7 is an ER-positive cell line. The cells were seeded into 24-well plates (70% confluence) and co-transfected with the constructs incorporating different ER&#x003b2; 3'UTRs (0.8 &#x003bc;g/well) and pRL-TK (Renilla plasmid, Promega, 0.02 &#x003bc;g/well), as internal control, using Lipofectamine 2000 (Invitrogen). Cells were harvested 24 h after transfection, and the activities of Firefly and Renilla luciferases were measured by the Dual Luciferase Reporter Assay System (Promega), using a Berthold FB12 Luminometer.</p></sec><sec><title>mRNA stability assay</title><p>The assay was performed on the HEK293 cell line. The cells were maintained in 50% of Dulbecco's modified Eagle's medium (Gibco), supplemented with 10% fetal bovine serum (Saveen Werner AB), 1% penicillin-streptomycin (Gibco), and 50% F12 Nutrient Mixture with L-glutamine (Gibco), at 37&#x000b0;C in 5% CO<sub>2</sub>. Cells were transfected with a total amount of 10 &#x003bc;g DNA at 90-95% confluence in 10-cm dishes, using Lipofectamine 2000 (Invitrogen). At the end of transfection (4-6 h after Lipofectamine treatment), cells were split into 6-well plates. Twenty-four hours later, cells were treated with 1 &#x003bc;g/ml actinomycin D (Sigma) [<xref ref-type="bibr" rid="B35">35</xref>] to suppress transcription. Cells were harvested 0 and 24 h after actinomycin D treatment. Total RNA was extracted using the RNeasy kit (Invitrogen). mRNA levels were assayed using the SYBRGreen PCR master mix (Applied Biosystems), with specific forward (5'-ATCCGGAAGCGACCAACG-3') and reverse primers (5'-CGGTAAGACCTTTCGGTACTTC-3'), which target the Luciferase part of the Luciferase-ER&#x003b2;3'UTR hybrid constructs. 18S rRNA levels, used for normalization, were measured using the Universal TaqMan PCR Master Mix and 20 &#x000d7; 18S Target Primers and Probe (all from Applied Biosystems). All Real-Time PCR experiments were performed on a 7500 Fast Real-Time PCR System (Applied Biosystems).</p></sec></sec><sec><title>Results</title><sec><title>mRNA levels of endogenous ER&#x003b2; alleles differ in heterozygous carriers for rs4986938, but not in heterozygous carriers for rs928554</title><p>To study a possible variation in allelic expression of endogenous transcripts in human tissues, we performed an allelic expression assay. In this assay, the relative mRNA levels of two alleles are determined by cDNA sequencing, and corrected for any difference in sequencing efficiency by normalizing with the sequence of genomic DNA from the same individuals [<xref ref-type="bibr" rid="B36">36</xref>]. A difference in relative mRNA levels for two alleles shows that the alleles differ with regard to mRNA levels, which could be the result of differences in transcription or mRNA stability. Figure <xref ref-type="fig" rid="F2">2</xref> shows that there is a significant difference in allelic expression of rs4986938, but not of rs928554.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Allelic expression of ER&#x003b2; 3'UTR SNPs in breast tumor samples</bold>. <bold>A</bold>. Genomic DNA was sequenced in two independent assays. cDNA synthesis was performed twice and each cDNA was sequenced in two independent assays. For each sample and allele, the average peak heights from the four cDNA sequencing assays were normalized by the average peak heights from the two DNA sequencing assays. The results from five breast tumor samples heterozygous for each SNP are presented as relative allelic ratios for cDNA versus genomic DNA. Data are shown as mean &#x000b1; SD, with allele G set to 100%. <bold>(a) </bold>ER&#x003b2;1 3'UTR polymorphism (rs4986938 G&#x02194;A); <bold>(b) </bold>ER&#x003b2;2 polymorphism (rs928554 G&#x02194;A).<bold>B</bold>. Representative examples of genomic DNA and mRNA sequencing. <bold>(a) </bold>ER&#x003b2;1 3'UTR polymorphism (rs4986938); <bold>(b) </bold>ER&#x003b2;2 3'UTR polymorphism (rs928554). Observe that for rs928554 G&#x02194;A, the bottom strand was sequenced therefore the DNA sequence reads C and T, respectively.</p></caption><graphic xlink:href="1471-2156-10-55-2"/></fig></sec><sec><title>ER&#x003b2; 3'UTR alleles display similar luciferase activities and mRNA stability</title><p>To study molecular effects of the different alleles of the 3'UTRs, we generated four plasmids with different alleles at investigated SNP positions. The created plasmids contained the ER&#x003b2; promoter, which regulates the expression of the reporter luciferase gene fused to 3'UTRs from ER&#x003b2;1 or ER&#x003b2;2, respectively (Figure <xref ref-type="fig" rid="F1">1B</xref>). A similar assay was successfully used in previous studies [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. This assay would capture any differences in mRNA stability and translatability. The luciferase activities of all constructs were measured in three different cell lines.</p><p>The luciferase activity of the plasmid ER&#x003b2;promPGL3, which carries the ER&#x003b2; promoter and SV40 poly(A) signal, was 9-fold higher comparing to the basic promoterless PGL3 vector, suggesting that the included ER&#x003b2; promoter fragment is transcriptionally functional (Figure <xref ref-type="fig" rid="F3">3A</xref>). The luciferase activities of the constructs including the ER&#x003b2; promoter and ER&#x003b2; 3'UTR (ER&#x003b2;promPGL3ER&#x003b2;UTR), were about 30% of that of ER&#x003b2;promPGL3, i.e. 3-fold higher compared to the basic promoterless PGL3 vector. This is expected since the SV40 poly(A) signal, which has high translational potency, was replaced by the less potent 3'UTR.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Relative luciferase activities of 3'UTR constructs assayed in three different cell lines</bold>. Relative luciferase activity is calculated as the ratio of Firefly luciferase activity vs. Renilla luciferase activity. Three human cell lines (HEK293, HeLa and MCF7) were co-transfected with 0.8 &#x003bc;g of the Firefly luciferase plasmids (PGL3 basic, ER&#x003b2;promPGL3, ER&#x003b2;promPGL3ER&#x003b2;1UTRG/A for rs4986938, ER&#x003b2;promPGL3ER&#x003b2;2UTRG/A for rs928554) and 0.02 &#x003bc;g Renilla luciferase plasmid as internal control, at 70% confluence in 24-well plates. Cells were harvested 24 h after transfection, and the activities of Firefly and Renilla luciferases were measured. Each measurement represents the average of three independent assays using independent plasmid preparations. Data are shown as mean &#x000b1; SD. <bold>A</bold>. The luciferase activity of generated constructs in HEK293 cells, is normalized to the basic PGL3 plasmid, whose activity is set to 100%. The same results were obtained in the two other cell lines (data not shown); <bold>B</bold>. ER&#x003b2;1 3'UTR polymorphism (rs4986938 G&#x02194;A);<bold>C</bold>. ER&#x003b2;2 polymorphism (rs928554 G&#x02194;A). The luciferase activity of allele G is set to 100%.</p></caption><graphic xlink:href="1471-2156-10-55-3"/></fig><p>There was no difference in luciferase activity between the two alleles of ER&#x003b2;1 3'UTR, in any of the three analyzed cell lines, suggesting that the investigated ER&#x003b2;1 3'UTR SNP does not influence the mRNA stability and translatability (Figure <xref ref-type="fig" rid="F3">3B</xref>). The same results were obtained for the two alleles of ER&#x003b2;2 3'UTR (Figure <xref ref-type="fig" rid="F3">3C</xref>).</p><p>In order to directly assay differences in mRNA stability between ER&#x003b2; 3'UTR alleles, we determined mRNA levels in cells transfected with the different plasmids, after inhibition of transcription with actinomycin D. Luciferase constructs were transfected into HEK293 cells. Twenty-four hours later, cells were treated with actinomycin D to suppress transcription. mRNA levels at 0 and 24 h after actinomycin D treatment were quantified by Real-Time PCR. As shown in Figure <xref ref-type="fig" rid="F4">4</xref>, there was no difference in mRNA levels, after inhibition of transcription with actinomycin D, between the two alleles, for the two analyzed SNPs, suggesting that the investigated ER&#x003b2; 3'UTR SNPs do not influence the mRNA stability.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>ER&#x003b2; 3'UTR mRNA stability in HEK293 cells</bold>. The cells were transfected with 10 &#x003bc;g of the respective luciferase plasmids (ER&#x003b2;promPGL3ER&#x003b2;1UTRG/A for rs4986938, and ER&#x003b2;promPGL3ER&#x003b2;2UTRG/A for rs928554) at 90-95% confluence in 10-cm dishes. Twenty-four hours after transfection, cells were split into 6-well plates (6 wells/samples for each construct in total, corresponding to triplicate assays at two time points), so that each well could receive the same amount of plasmid. Twenty-four hours later, cells were treated with 1 &#x003bc;g/ml actinomycin D to suppress transcription. Cells were harvested 0 and 24 h after actinomycin D treatment, with triplicate samples for each time point. The whole experiment was performed twice, with reproducible results. One representative experiment is shown. Data are shown as mean &#x000b1; SD, normalized to 18s, with the 0 h time point set to 100%. <bold>A</bold>. ER&#x003b2;1 3'UTR polymorphism (rs4986938 G&#x02194;A); <bold>B</bold>. ER&#x003b2;2 polymorphism (rs928554 G&#x02194;A).</p></caption><graphic xlink:href="1471-2156-10-55-4"/></fig></sec><sec><title>The predicted secondary structures of ER&#x003b2; 3'UTR mRNAs suggest no differences in stability for the two alleles</title><p>We have investigated the secondary structures of ER&#x003b2; 3'UTRs, using the Mfold web server for nucleic acid folding and hybridization prediction [<xref ref-type="bibr" rid="B38">38</xref>]. We compared ER&#x003b2; 3'UTR sequences investigated in this study. Each of the four analyzed ER&#x003b2; 3'UTRs can form a number of secondary structures. Focusing on the structures with the lowest free energy, i.e. the highest stability, no statistical difference was found between free energies for the G and A alleles of rs4986938, or for the G and A alleles of rs928554 (data not shown), supporting the results of the experimental mRNA stability assay.</p></sec></sec><sec><title>Discussion</title><p>SNPs that change the primary structure of the protein have not been reported for ER&#x003b2;. However, there are reports of SNPs in promoter regions and 3'UTRs that could potentially alter mRNA and protein levels. In this study, we investigated the effects of two commonly studied SNPs, rs4986938 and rs928554, in the 3'UTRs of ER&#x003b2;, on mRNA stability and translatability.</p><p>In order to study a possible variation in mRNA expression of transcripts that include the different alleles of the two SNPs, we have assayed mRNA levels in breast cancer samples which are heterozygotes for either of the two SNPs. Significant difference in mRNA expression of the different alleles was observed for the SNP in ER&#x003b2;1 3'UTR, but not for the SNP in ER&#x003b2;2 3'UTR.</p><p>ER&#x003b2; SNPs have been found to have a large amount of linkage disequilibrium (LD) [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. According to the HAPMAP haploblock structure, there are several additional SNPs surrounding rs498693, which are in LD with rs498693. Thus, we further investigated the molecular effects of this SNP independent from other polymorphisms using an <italic>in vitro </italic>assay, where investigated ER&#x003b2; sequences are identical except for the SNP under investigation. Future studies should aim at investigating the effects of SNPs that are in LD with rs498693on mRNA levels.</p><p>The two ER&#x003b2; SNPs were analyzed in cell lines that express or do not express endogenous ERs. We initially employed an assay that simultaneously detects differences in mRNA stability and translatability. This was complemented with an assay that directly detects differences in mRNA stability.</p><p>Luciferase reporter genes enable easy detection of changes in transcript and protein stability. Furthermore, studying isolated 3'UTRs in the context of a recombinant mRNA avoids confounding effects of additional genetic variations when assaying endogenous alleles. Also, measuring luciferase mRNA and protein as compared to ER&#x003b2; mRNA and protein, avoids potential problems of distinguishing the molecules under investigation from any endogenous mRNA and protein. Neither of the two <italic>in vitro </italic>assays showed an effect of the different alleles of ER&#x003b2; SNPs on mRNA stability or translatability.</p><p>It is also of importance to note that, although there are studies that associate these two SNPs with many different disorders, there are also studies which do not provide such evidence, even for the same disease. For example, our study of a Swedish cohort associated both rs4986938 and rs928554 with bulimia [<xref ref-type="bibr" rid="B10">10</xref>], while a study of a German cohort did not [<xref ref-type="bibr" rid="B9">9</xref>]. An investigation of a Danish cohort of postmenopausal women associated rs4986938 with bone mineral density [<xref ref-type="bibr" rid="B12">12</xref>], whereas an American study of a cohort of premenopausal women did not [<xref ref-type="bibr" rid="B40">40</xref>]. One study associated rs4986938 with the risk of endometriosis in a Korean population, but not in a Japanese population [<xref ref-type="bibr" rid="B41">41</xref>].</p><p>There are many reasons which could explain the inconsistency between different studies in showing association of, or lack of association of, SNPs in the ER&#x003b2; 3'UTR with a particular disease. In relation to the studies in this paper, which suggest that the effects observed for the SNP in ER&#x003b2;1 3'UTR on mRNA levels could be due to LD with another variant affecting mRNA levels, the haploblock structure and thus the LD vary between different populations. If a SNP that has not been the focus of most studies causes a phenotype, depending on the LD in a particular population, it might or might not be in LD with the investigated SNPs.</p><p>Finally, 3'UTRs of many protein-coding genes are found to be targets for miRNAs, short RNAs that regulate repression of translation. According to the miRNA database [<xref ref-type="bibr" rid="B42">42</xref>], ER&#x003b2; can be a target for a number of miRNAs. However, none of them corresponds to the 3'UTR sequences where the SNPs in focus are located, although such miRNAs may exist, but remain to be identified.</p></sec><sec><title>Conclusion</title><p>In summary, we have demonstrated a significant difference in allelic expression of rs4986938, but not of rs928554, in breast tumor tissues from heterozygous individuals. Our studies do not support the hypothesis that the two commonly studied ER&#x003b2; SNPs change estrogen signaling by affecting ER&#x003b2; mRNA stability or protein translatability. Combined, our results suggest that the observed associations between ER&#x003b2; 3'UTR SNPs and disease susceptibility are due to LD with another gene variant effecting mRNA levels.</p></sec><sec><title>Authors' contributions</title><p>MP carried out the experimental work and drafted the manuscript. CZ and KDW designed the study, supervised the experimental work and helped to draft the manuscript. JAG participated in the coordination of the study and drafting of the manuscript. All authors read, edited and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Eric W-F Lam from Charing Cross Hospital, London, for providing breast tumor tissue samples used in allelic expression assay. The study was approved by the ethical committee of the Karolinska Institute, and supported by the EU project CRESCENDO.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name><name><surname>Cavailles</surname><given-names>V</given-names></name><name><surname>Fuqua</surname><given-names>SA</given-names></name><name><surname>Jordan</surname><given-names>VC</given-names></name><name><surname>Katzenellenbogen</surname><given-names>JA</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name><name><surname>Maggi</surname><given-names>A</given-names></name><name><surname>Muramatsu</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>MG</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>International Union of Pharmacology. LXIV. Estrogen receptors</article-title><source>Pharmacol Rev</source><year>2006</year><volume>58</volume><fpage>773</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">17132854</pub-id><pub-id pub-id-type="doi">10.1124/pr.58.4.8</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herynk</surname><given-names>MH</given-names></name><name><surname>Fuqua</surname><given-names>SA</given-names></name></person-group><article-title>Estrogen receptor mutations in human disease</article-title><source>Endocr Rev</source><year>2004</year><volume>25</volume><fpage>869</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">15583021</pub-id><pub-id pub-id-type="doi">10.1210/er.2003-0010</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>LC</given-names></name><name><surname>Watson</surname><given-names>P</given-names></name></person-group><article-title>Steroid receptors in human breast tumorigenesis and breast cancer progression</article-title><source>Biomed Pharmacother</source><year>2002</year><volume>56</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">12000137</pub-id><pub-id pub-id-type="doi">10.1016/S0753-3322(01)00157-3</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Speirs</surname><given-names>V</given-names></name></person-group><article-title>Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?</article-title><source>J Pathol</source><year>2002</year><volume>197</volume><fpage>143</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12015736</pub-id><pub-id pub-id-type="doi">10.1002/path.1072</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>Estrogen receptor beta: an overview and update</article-title><source>Nucl Recept Signal</source><year>2008</year><volume>6</volume><fpage>e003</fpage><pub-id pub-id-type="pmid">18301783</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Lam</surname><given-names>EW</given-names></name><name><surname>Sunters</surname><given-names>A</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>De Bella</surname><given-names>MT</given-names></name><name><surname>Coombes</surname><given-names>RC</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name></person-group><article-title>Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>7600</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14576822</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207100</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>LC</given-names></name><name><surname>Yeh</surname><given-names>CC</given-names></name><name><surname>Nojima</surname><given-names>D</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Cloning and characterization of human estrogen receptor beta promoter</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>275</volume><fpage>682</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10964723</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.2000.3363</pub-id></citation></ref><ref id="B8"><citation citation-type="other"><article-title>SNP database</article-title><ext-link ext-link-type="uri" xlink:href="http://snpper.chip.org/"/></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenkranz</surname><given-names>K</given-names></name><name><surname>Hinney</surname><given-names>A</given-names></name><name><surname>Ziegler</surname><given-names>A</given-names></name><name><surname>Hermann</surname><given-names>H</given-names></name><name><surname>Fichter</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>H</given-names></name><name><surname>Siegfried</surname><given-names>W</given-names></name><name><surname>Young</surname><given-names>JK</given-names></name><name><surname>Remschmidt</surname><given-names>H</given-names></name><name><surname>Hebebrand</surname><given-names>J</given-names></name></person-group><article-title>Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: identification of several genetic variants</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><fpage>4524</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9851804</pub-id><pub-id pub-id-type="doi">10.1210/jc.83.12.4524</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Naessen</surname><given-names>S</given-names></name><name><surname>Dahlman</surname><given-names>I</given-names></name><name><surname>Linden Hirschberg</surname><given-names>A</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name></person-group><article-title>Association of estrogen receptor beta gene polymorphisms with bulimic disease in women</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">14699439</pub-id><pub-id pub-id-type="doi">10.1038/sj.mp.4001402</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reimann</surname><given-names>M</given-names></name><name><surname>Vafeiadou</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>WL</given-names></name><name><surname>Dierkes</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Huebner</surname><given-names>U</given-names></name><name><surname>Hallund</surname><given-names>J</given-names></name><name><surname>Bugel</surname><given-names>S</given-names></name><name><surname>Branca</surname><given-names>F</given-names></name><name><surname>Williams</surname><given-names>CM</given-names></name><name><surname>Koebnick</surname><given-names>C</given-names></name></person-group><article-title>Evidence for associations between common polymorphisms of estrogen receptor beta gene with homocysteine and nitric oxide</article-title><source>Climacteric</source><year>2006</year><volume>9</volume><fpage>215</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16766435</pub-id><pub-id pub-id-type="doi">10.1080/13697130600733758</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silvestri</surname><given-names>S</given-names></name><name><surname>Thomsen</surname><given-names>AB</given-names></name><name><surname>Gozzini</surname><given-names>A</given-names></name><name><surname>Bagger</surname><given-names>Y</given-names></name><name><surname>Christiansen</surname><given-names>C</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name></person-group><article-title>Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?</article-title><source>Menopause</source><year>2006</year><volume>13</volume><fpage>451</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">16735942</pub-id><pub-id pub-id-type="doi">10.1097/01.gme.0000182804.14385.a2</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sundarrajan</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>WX</given-names></name><name><surname>Roy</surname><given-names>AC</given-names></name><name><surname>Ng</surname><given-names>SC</given-names></name></person-group><article-title>Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>135</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11231990</pub-id><pub-id pub-id-type="doi">10.1210/jc.86.1.135</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Choi</surname><given-names>YM</given-names></name><name><surname>Choung</surname><given-names>SH</given-names></name><name><surname>Yoon</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>GH</given-names></name><name><surname>Moon</surname><given-names>SY</given-names></name></person-group><article-title>Estrogen receptor beta gene +1730 G/A polymorphism in women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2009</year><pub-id pub-id-type="pmid">19185861</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westberg</surname><given-names>L</given-names></name><name><surname>Hakansson</surname><given-names>A</given-names></name><name><surname>Melke</surname><given-names>J</given-names></name><name><surname>Shahabi</surname><given-names>HN</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Buervenich</surname><given-names>S</given-names></name><name><surname>Carmine</surname><given-names>A</given-names></name><name><surname>Ahlberg</surname><given-names>J</given-names></name><name><surname>Grundell</surname><given-names>MB</given-names></name><name><surname>Schulhof</surname><given-names>B</given-names></name><name><surname>Klingborg</surname><given-names>K</given-names></name><name><surname>Holmberg</surname><given-names>B</given-names></name><name><surname>Sydow</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>L</given-names></name><name><surname>Johnels</surname><given-names>EB</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><name><surname>Nissbrandt</surname><given-names>H</given-names></name></person-group><article-title>Association between the estrogen receptor beta gene and age of onset of Parkinson's disease</article-title><source>Psychoneuroendocrinology</source><year>2004</year><volume>29</volume><fpage>993</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15219649</pub-id><pub-id pub-id-type="doi">10.1016/j.psyneuen.2003.08.010</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kisiel</surname><given-names>B</given-names></name><name><surname>Bednarczuk</surname><given-names>T</given-names></name><name><surname>Kostrzewa</surname><given-names>G</given-names></name><name><surname>Kosinska</surname><given-names>J</given-names></name><name><surname>Miskiewicz</surname><given-names>P</given-names></name><name><surname>Plazinska</surname><given-names>MT</given-names></name><name><surname>Bar-Andziak</surname><given-names>E</given-names></name><name><surname>Krolicki</surname><given-names>L</given-names></name><name><surname>Krajewski</surname><given-names>P</given-names></name><name><surname>Ploski</surname><given-names>R</given-names></name></person-group><article-title>Polymorphism of the oestrogen receptor beta gene (ESR2) is associated with susceptibility to Graves' disease</article-title><source>Clin Endocrinol (Oxf)</source><year>2008</year><volume>68</volume><fpage>429</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">17941906</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>A</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Mizutani</surname><given-names>Y</given-names></name><name><surname>Furuya</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Association study using single nucleotide polymorphisms in the estrogen receptor beta (ESR2) gene for preeclampsia</article-title><source>Hypertens Res</source><year>2004</year><volume>27</volume><fpage>903</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15894829</pub-id><pub-id pub-id-type="doi">10.1291/hypres.27.903</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forsti</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Israelsson</surname><given-names>E</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name></person-group><article-title>Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association</article-title><source>Breast Cancer Res Treat</source><year>2003</year><volume>79</volume><fpage>409</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12846425</pub-id><pub-id pub-id-type="doi">10.1023/A:1024020609833</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maguire</surname><given-names>P</given-names></name><name><surname>Margolin</surname><given-names>S</given-names></name><name><surname>Skoglund</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>XF</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name></person-group><article-title>Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2005</year><volume>94</volume><fpage>145</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16261413</pub-id><pub-id pub-id-type="doi">10.1007/s10549-005-7697-7</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Georgopoulos</surname><given-names>NA</given-names></name><name><surname>Adonakis</surname><given-names>GL</given-names></name><name><surname>Fotopoulos</surname><given-names>A</given-names></name><name><surname>Koika</surname><given-names>V</given-names></name><name><surname>Spinos</surname><given-names>N</given-names></name><name><surname>Saltamavros</surname><given-names>A</given-names></name><name><surname>Keramopoulos</surname><given-names>A</given-names></name><name><surname>Koukouras</surname><given-names>D</given-names></name><name><surname>Decavalas</surname><given-names>G</given-names></name><name><surname>Kourounis</surname><given-names>GS</given-names></name></person-group><article-title>Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer</article-title><source>Gynecol Endocrinol</source><year>2006</year><volume>22</volume><fpage>185</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16723304</pub-id><pub-id pub-id-type="doi">10.1080/09513590600645767</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>B</given-names></name><name><surname>Kalush</surname><given-names>F</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>K</given-names></name><name><surname>Mitra</surname><given-names>N</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Lippert</surname><given-names>R</given-names></name><name><surname>Halldorsson</surname><given-names>BV</given-names></name><name><surname>Woodworth</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>T</given-names></name><name><surname>Clark</surname><given-names>AG</given-names></name><name><surname>Parl</surname><given-names>FF</given-names></name><name><surname>Broder</surname><given-names>S</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name></person-group><article-title>Estrogen receptor genotypes and haplotypes associated with breast cancer risk</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>8891</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">15604249</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1256</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><collab>Breast and Prostate Cancer Cohort Consortium</collab><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Bretsky</surname><given-names>P</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Pharoah</surname><given-names>P</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Amiano</surname><given-names>P</given-names></name><name><surname>Berglund</surname><given-names>G</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Buring</surname><given-names>J</given-names></name><name><surname>Burtt</surname><given-names>N</given-names></name><name><surname>Calle</surname><given-names>EE</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Clavel-Chapelon</surname><given-names>F</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Hirschhorn</surname><given-names>J</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Hoover</surname><given-names>R</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Kolonel</surname><given-names>L</given-names></name><name><surname>LeMarchand</surname><given-names>L</given-names></name><name><surname>Lund</surname><given-names>E</given-names></name><name><surname>Palli</surname><given-names>D</given-names></name><name><surname>Peeters</surname><given-names>PH</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Thun</surname><given-names>M</given-names></name><name><surname>Tjonneland</surname><given-names>A</given-names></name><name><surname>Travis</surname><given-names>RC</given-names></name><name><surname>Trichopoulos</surname><given-names>D</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name></person-group><article-title>Haplotypes of the estrogen receptor beta gene and breast cancer risk</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><fpage>387</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17935138</pub-id><pub-id pub-id-type="doi">10.1002/ijc.23127</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>TA</given-names></name></person-group><article-title>Regulation of gene expression by alternative untranslated regions</article-title><source>Trends Genet</source><year>2006</year><volume>22</volume><fpage>119</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16430990</pub-id><pub-id pub-id-type="doi">10.1016/j.tig.2006.01.001</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Moor</surname><given-names>CH</given-names></name><name><surname>Meijer</surname><given-names>H</given-names></name><name><surname>Lissenden</surname><given-names>S</given-names></name></person-group><article-title>Mechanisms of translational control by the 3' UTR in development and differentiation</article-title><source>Semin Cell Dev Biol</source><year>2005</year><volume>16</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">15659339</pub-id><pub-id pub-id-type="doi">10.1016/j.semcdb.2004.11.007</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazumder</surname><given-names>B</given-names></name><name><surname>Seshadri</surname><given-names>V</given-names></name><name><surname>Fox</surname><given-names>PL</given-names></name></person-group><article-title>Translational control by the 3'-UTR: the ends specify the means</article-title><source>Trends Biochem Sci</source><year>2003</year><volume>28</volume><fpage>91</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12575997</pub-id><pub-id pub-id-type="doi">10.1016/S0968-0004(03)00002-1</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Gherzi</surname><given-names>R</given-names></name><name><surname>Ong</surname><given-names>SE</given-names></name><name><surname>Chan</surname><given-names>EL</given-names></name><name><surname>Raijmakers</surname><given-names>R</given-names></name><name><surname>Pruijn</surname><given-names>GJ</given-names></name><name><surname>Stoecklin</surname><given-names>G</given-names></name><name><surname>Moroni</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>AU binding proteins recruit the exosome to degrade ARE-containing mRNAs</article-title><source>Cell</source><year>2001</year><volume>107</volume><fpage>451</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">11719186</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00578-5</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fenger-Gr&#x000f8;n</surname><given-names>M</given-names></name><name><surname>Fillman</surname><given-names>C</given-names></name><name><surname>Norrild</surname><given-names>B</given-names></name><name><surname>Lykke-Andersen</surname><given-names>J</given-names></name></person-group><article-title>Multiple processing body factors and the ARE binding protein TTP activate mRNA decapping</article-title><source>Mol Cell</source><year>2005</year><volume>20</volume><fpage>905</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">16364915</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2005.10.031</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNAs: target recognition and regulatory functions</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>215</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">19167326</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.002</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Lam</surname><given-names>EW</given-names></name><name><surname>Sunters</surname><given-names>A</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>De Bella</surname><given-names>MT</given-names></name><name><surname>Coombes</surname><given-names>RC</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name></person-group><article-title>Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>7600</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">14576822</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207100</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>H</given-names></name><name><surname>Toyama</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Iwase</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name></person-group><article-title>Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer</article-title><source>Jpn J Clin Oncol</source><year>2007</year><volume>37</volume><fpage>820</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17932113</pub-id><pub-id pub-id-type="doi">10.1093/jjco/hym114</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>J</given-names></name><name><surname>Str&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>Estrogen receptor beta in breast cancer--diagnostic and therapeutic implications</article-title><source>Steroids</source><year>2009</year><volume>74</volume><fpage>635</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19463683</pub-id><pub-id pub-id-type="doi">10.1016/j.steroids.2009.02.005</pub-id></citation></ref><ref id="B32"><citation citation-type="other"><article-title>Macrogen DNA Sequencing Service</article-title><ext-link ext-link-type="uri" xlink:href="http://dna.macrogen.com/eng/"/></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahlert</surname><given-names>S</given-names></name><name><surname>Nuedling</surname><given-names>S</given-names></name><name><surname>van Eickels</surname><given-names>M</given-names></name><name><surname>Vetter</surname><given-names>H</given-names></name><name><surname>Meyer</surname><given-names>R</given-names></name><name><surname>Grohe</surname><given-names>C</given-names></name></person-group><article-title>Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>18447</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10749889</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M910345199</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vivacqua</surname><given-names>A</given-names></name><name><surname>Bonofiglio</surname><given-names>D</given-names></name><name><surname>Albanito</surname><given-names>L</given-names></name><name><surname>Madeo</surname><given-names>A</given-names></name><name><surname>Rago</surname><given-names>V</given-names></name><name><surname>Carpino</surname><given-names>A</given-names></name><name><surname>Musti</surname><given-names>AM</given-names></name><name><surname>Picard</surname><given-names>D</given-names></name><name><surname>Ando</surname><given-names>S</given-names></name><name><surname>Maggiolini</surname><given-names>M</given-names></name></person-group><article-title>17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30</article-title><source>Mol Pharmacol</source><year>2006</year><volume>70</volume><fpage>1414</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16835357</pub-id><pub-id pub-id-type="doi">10.1124/mol.106.026344</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Pitarque</surname><given-names>M</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group><article-title>3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>340</volume><fpage>491</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16378601</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.12.035</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pastinen</surname><given-names>T</given-names></name><name><surname>Sladek</surname><given-names>R</given-names></name><name><surname>Gurd</surname><given-names>S</given-names></name><name><surname>Sammak</surname><given-names>A</given-names></name><name><surname>Ge</surname><given-names>B</given-names></name><name><surname>Lepage</surname><given-names>P</given-names></name><name><surname>Lavergne</surname><given-names>K</given-names></name><name><surname>Villeneuve</surname><given-names>A</given-names></name><name><surname>Gaudin</surname><given-names>T</given-names></name><name><surname>Br&#x000e4;ndstr&#x000f6;m</surname><given-names>H</given-names></name><name><surname>Beck</surname><given-names>A</given-names></name><name><surname>Verner</surname><given-names>A</given-names></name><name><surname>Kingsley</surname><given-names>J</given-names></name><name><surname>Harmsen</surname><given-names>E</given-names></name><name><surname>Labuda</surname><given-names>D</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Vohl</surname><given-names>MC</given-names></name><name><surname>Naumova</surname><given-names>AK</given-names></name><name><surname>Sinnett</surname><given-names>D</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name></person-group><article-title>A survey of genetic and epigenetic variation affecting human gene expression</article-title><source>Physiol Genomics</source><year>2004</year><volume>16</volume><fpage>184</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">14583597</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popowski</surname><given-names>K</given-names></name><name><surname>Sperker</surname><given-names>B</given-names></name><name><surname>Kroemer</surname><given-names>HK</given-names></name><name><surname>John</surname><given-names>U</given-names></name><name><surname>Laule</surname><given-names>M</given-names></name><name><surname>Stangl</surname><given-names>K</given-names></name><name><surname>Cascorbi</surname><given-names>I</given-names></name></person-group><article-title>Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene</article-title><source>Pharmacogenetics</source><year>2003</year><volume>13</volume><fpage>445</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">12893982</pub-id><pub-id pub-id-type="doi">10.1097/00008571-200308000-00002</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zuker</surname><given-names>M</given-names></name></person-group><article-title>Mfold web server for nucleic acid folding and hybridization prediction</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>3406</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12824337</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkg595</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Dahlman</surname><given-names>I</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Arner</surname><given-names>P</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K</given-names></name></person-group><article-title>Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis--a cohort study</article-title><source>BMC Med Genet</source><year>2007</year><volume>8</volume><fpage>73</fpage><pub-id pub-id-type="pmid">18053221</pub-id><pub-id pub-id-type="doi">10.1186/1471-2350-8-73</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ichikawa</surname><given-names>S</given-names></name><name><surname>Koller</surname><given-names>DL</given-names></name><name><surname>Peacock</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>ML</given-names></name><name><surname>Lai</surname><given-names>D</given-names></name><name><surname>Hui</surname><given-names>SL</given-names></name><name><surname>Johnston</surname><given-names>CC</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Econs</surname><given-names>MJ</given-names></name></person-group><article-title>Polymorphisms in the estrogen receptor beta (ESR2) gene are associated with bone mineral density in Caucasian men and women</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>5921</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16118344</pub-id><pub-id pub-id-type="doi">10.1210/jc.2004-2253</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>YM</given-names></name><name><surname>Suh</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Moon</surname><given-names>SY</given-names></name></person-group><article-title>Estrogen receptor beta gene +1730 G/A polymorphism in women with endometriosis</article-title><source>Fertil Steril</source><year>2007</year><volume>88</volume><fpage>785</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17336962</pub-id><pub-id pub-id-type="doi">10.1016/j.fertnstert.2006.12.032</pub-id></citation></ref><ref id="B42"><citation citation-type="other"><article-title>miRNA database</article-title><ext-link ext-link-type="uri" xlink:href="http://microrna.sanger.ac.uk/sequences/"/></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rexrode</surname><given-names>KM</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hegener</surname><given-names>HH</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Zee</surname><given-names>RY</given-names></name></person-group><article-title>Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women</article-title><source>Clin Chem</source><year>2007</year><volume>53</volume><fpage>1749</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">17702854</pub-id><pub-id pub-id-type="doi">10.1373/clinchem.2007.091454</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Hamada</surname><given-names>GS</given-names></name><name><surname>Nishimoto</surname><given-names>IN</given-names></name><name><surname>Netto</surname><given-names>MM</given-names></name><name><surname>Motola</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Laginha</surname><given-names>FM</given-names></name><name><surname>Kasuga</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Onuma</surname><given-names>H</given-names></name><name><surname>Nishimura</surname><given-names>H</given-names></name><name><surname>Kusama</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Ishihara</surname><given-names>J</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Hanaoka</surname><given-names>T</given-names></name><name><surname>Tsugane</surname><given-names>S</given-names></name></person-group><article-title>Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians</article-title><source>Cancer Sci</source><year>2009</year><volume>100</volume><fpage>927</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">19298602</pub-id><pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01118.x</pub-id></citation></ref><ref id="B45"><citation citation-type="other"><article-title>Database of common gene variations in the Japanese population</article-title><ext-link ext-link-type="uri" xlink:href="http://snp.ims.u-tokyo.ac.jp/"/></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dresner-Pollak</surname><given-names>R</given-names></name><name><surname>Kinnar</surname><given-names>T</given-names></name><name><surname>Friedlander</surname><given-names>Y</given-names></name><name><surname>Sharon</surname><given-names>N</given-names></name><name><surname>Rosenmann</surname><given-names>H</given-names></name><name><surname>Pollak</surname><given-names>A</given-names></name></person-group><article-title>Estrogen receptor beta gene variant is associated with vascular dementia in elderly women</article-title><source>Genet Test Mol Biomarkers</source><year>2009</year><volume>13</volume><fpage>339</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">19473078</pub-id><pub-id pub-id-type="doi">10.1089/gtmb.2008.0129</pub-id></citation></ref></ref-list></back></article> 